Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists.
J Med Chem
; 50(2): 272-82, 2007 Jan 25.
Article
em En
| MEDLINE
| ID: mdl-17228869
ABSTRACT
A series of biphenylaminocyclopropane carboxamide based bradykinin B1 receptor antagonists has been developed that possesses good pharmacokinetic properties and is CNS penetrant. Discovery that the replacement of the trifluoropropionamide in the lead structure with polyhaloacetamides, particularly a trifluoroacetamide, significantly reduced P-glycoprotein mediated efflux for the series proved essential. One of these novel bradykinin B1 antagonists (13b) also exhibited suitable pharmacokinetic properties and efficient ex vivo receptor occupancy for further development as a novel approach for the treatment of pain and inflammation.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Medula Espinal
/
Benzoatos
/
Encéfalo
/
Ciclopropanos
/
Antagonistas de Receptor B1 da Bradicinina
/
Amidas
/
Compostos de Aminobifenil
/
Acetamidas
Idioma:
En
Ano de publicação:
2007
Tipo de documento:
Article
País de afiliação:
Estados Unidos